Monday Sep 8
Theravance Biopharma Announces Positive Top-Line Results from Phase...
The study evaluated four doses of TD-4208 and placebo, administered once daily for 28 days in a double-blind, parallel group study in a total of 355 patients with moderate-to-severe COPD. TD-4208 met the primary efficacy endpoint at once-daily doses of 88, 175 and 350 mcg, with statistically significant changes versus placebo in trough FEV1 of 187 mL, 167 mL and 171 mL, respectively.
Theravance Sets New 12-Month Low at $20.43
Theravance shares reached a new 52-week low on Friday , American Banking & Market News reports. The company traded as low as $20.43 and last traded at $20.66, with a volume of 204,426 shares trading hands.
Theravance Biopharma to Present at Investor Conferences in September 2014
Theravance Biopharma, Inc. announced today that Rick E Winningham, Theravance Biopharma's Chief Executive Officer, is scheduled to present at the following investor conferences in September 2014: Baird 2014 Health Care Conference The New York Palace, New York, New York Thursday, September 4, 2014 2:35 p.m. EDT The presentations will be webcast live ... (more)
Theravance Biopharma: Neglected Spinoff Targeting A Huge Underserved Market
Theravance is probably a familiar name to many of you. The pharmaceutical company has received extensive coverage on Seeking Alpha over the years.
Theravance (THRX) Announces Quarterly Earnings Results, Beats Estimates By $0.35 EPS
Theravance posted its quarterly earnings results on Monday. The company reported earnings per share for the quarter, beating the consensus estimate of by $0.35, American Banking News.com reports.